MetaVia Inc (MTVA)

NASDAQ
Currency in USD
0.6845
+0.0087(+1.29%)
Closed·
After Hours
0.6899+0.0054(+0.7889%)
·
MTVA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
MTVA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.65540.6983
52 wk Range
0.64705.3000
Key Statistics
Edit
Prev. Close
0.6758
Open
0.66
Day's Range
0.6554-0.6983
52 wk Range
0.647-5.3
Volume
82.62K
Average Volume (3m)
508.35K
1-Year Change
-85.12%
Book Value / Share
0.51
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MTVA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.5000
Upside
+2,164.43%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

MetaVia Company Profile

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.

Compare MTVA to Peers and Sector

Metrics to compare
MTVA
Peers
Sector
Relationship
P/E Ratio
−0.2x−3.4x−0.5x
PEG Ratio
−0.010.000.00
Price/Book
1.4x1.8x2.6x
Price / LTM Sales
-25.6x2.9x
Upside (Analyst Target)
-200.3%49.4%
Fair Value Upside
Unlock−2.8%8.2%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 15.5000
(+2,164.43% Upside)

Earnings

Latest Release
Mar 20, 2025
EPS / Forecast
-0.51 / -0.98
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

8.1600
RNAZ
+6.67%
0.0847
ONCO
+13.54%
10.1900
UPXI
+6.37%
0.067
AGMH
+11.67%
0.3049
JYD
+3.39%

FAQ

What Is the MetaVia (MTVA) Stock Price Today?

The MetaVia stock price today is 0.68

What Stock Exchange Does MetaVia Trade On?

MetaVia is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for MetaVia?

The stock symbol for MetaVia is "MTVA."

What Is the MetaVia Market Cap?

As of today, MetaVia market cap is 5.92M.

What Is MetaVia's Earnings Per Share (TTM)?

The MetaVia EPS (TTM) is -2.71.

From a Technical Analysis Perspective, Is MTVA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.